Last reviewed · How we verify

Grazaoprevir/Elbasavir

The HIV Netherlands Australia Thailand Research Collaboration · FDA-approved active Small molecule

Grazaoprevir/Elbasavir is a Direct-acting antiviral (DAA) combination Small molecule drug developed by The HIV Netherlands Australia Thailand Research Collaboration. It is currently FDA-approved for Chronic hepatitis C virus (HCV) infection, genotypes 1-6.

Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication.

Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, genotypes 1-6.

At a glance

Generic nameGrazaoprevir/Elbasavir
SponsorThe HIV Netherlands Australia Thailand Research Collaboration
Drug classDirect-acting antiviral (DAA) combination
TargetHCV NS3/4A protease and NS5A protein
ModalitySmall molecule
Therapeutic areaVirology/Hepatology
PhaseFDA-approved

Mechanism of action

Grazoprevir is a direct-acting antiviral (DAA) that targets the NS3/4A serine protease essential for HCV polyprotein processing. Elbasavir targets the NS5A protein, which is critical for viral RNA replication and virion assembly. Together, this fixed-dose combination provides dual inhibition of key HCV enzymes, achieving high cure rates across multiple genotypes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Grazaoprevir/Elbasavir

What is Grazaoprevir/Elbasavir?

Grazaoprevir/Elbasavir is a Direct-acting antiviral (DAA) combination drug developed by The HIV Netherlands Australia Thailand Research Collaboration, indicated for Chronic hepatitis C virus (HCV) infection, genotypes 1-6.

How does Grazaoprevir/Elbasavir work?

Grazoprevir inhibits hepatitis C virus NS3/4A protease while elbasavir inhibits NS5A protein, blocking viral replication.

What is Grazaoprevir/Elbasavir used for?

Grazaoprevir/Elbasavir is indicated for Chronic hepatitis C virus (HCV) infection, genotypes 1-6.

Who makes Grazaoprevir/Elbasavir?

Grazaoprevir/Elbasavir is developed and marketed by The HIV Netherlands Australia Thailand Research Collaboration (see full The HIV Netherlands Australia Thailand Research Collaboration pipeline at /company/the-hiv-netherlands-australia-thailand-research-collaboration).

What drug class is Grazaoprevir/Elbasavir in?

Grazaoprevir/Elbasavir belongs to the Direct-acting antiviral (DAA) combination class. See all Direct-acting antiviral (DAA) combination drugs at /class/direct-acting-antiviral-daa-combination.

What development phase is Grazaoprevir/Elbasavir in?

Grazaoprevir/Elbasavir is FDA-approved (marketed).

What are the side effects of Grazaoprevir/Elbasavir?

Common side effects of Grazaoprevir/Elbasavir include Headache, Fatigue, Nausea, Diarrhea.

What does Grazaoprevir/Elbasavir target?

Grazaoprevir/Elbasavir targets HCV NS3/4A protease and NS5A protein and is a Direct-acting antiviral (DAA) combination.

Related